BETADINE® LEADS THE FIGHT AGAINST HAND FOOT AND MOUTH DISEASE (HFMD) INFECTION

3월 15, 2016 - 3 minutes read

SINGAPORE, 15 March 2016 – New research has highlighted the effectiveness of BETADINE®products in the fight against Hand Foot and Mouth Disease (HFMD), a viral infection that affects thousands of young children  each year.

There is a high incidence of HFMD in Asia. The World Health Organisation (WHO) recorded approximately 2.5 million cases in China, Japan, Singapore, Vietnam and Hong Kong in 2015, with 2 million cases registered in China alone. . According to WHO Guidelines, there are no specific antiviral drugs to treat HFMD.

In particular, BETADINE® Sore Throat Spray, Skin Cleanser, Gargle and Mouthwash demonstrated anti-virus effectiveness against the EV 71 and CA 16 viruses.   The EV 71 virus is known to cause neurological complications.

HFMD spreads from person-to-person through direct contact with nose and throat discharge, saliva, fluid from blisters or the stool of infected persons. While adults can be affected, children under five years of age are particularly susceptible and hence even the act of putting foreign objects like toys in the mouth at school and at home can lead to transmission from one child to the other. Although the risk of transmission of HFMD viruses is higher in crowded areas, the risk of infection can be lowered by good hygiene practices and prompt medical attention. It is also encouraged to avoid close contact such as kissing, hugging and sharing utensils.

Apart from BETADINE® Mouthwash and Gargle and Throat Spray’s germicidal protective hygiene role, they are also very effective in the treatment of sore throats,

which are a common occurrence in HFMD sufferers. Patients with HFMD can also experience fever, poor appetite and malaise within the first 2 days of the appearance of HFMD symptoms.

 

References:

  1. Ministry of Health (Singapore) – Hand, Foot & Mouth Disease

® : BETADINE  is a Registered Trademark

 

For further information please contact:

Stephenie Vasko
Communications Director- Asia, Latin America & Middle East
+65 6303 9732
stephenie.vasko@www.mundipharma.co.kr

About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as severe pain, oncology, respiratory disease rheumatoid arthritis, antiseptics and laxatives.

For more information please visit: www.www.mundipharma.co.kr